Clinical Trial

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-09-13; most recent amendment 2026-03-18.
Status change: Recruiting → Active, Not Recruiting 2026-01-12
Status change: Not Yet Recruiting → Recruiting 2024-11-07
Trial Details
NCT Number NCT06598462
Lead Sponsor Uniquity One (UNI)
Conditions Eosinophilic Esophagitis (EoE)
Enrollment 184 participants
Start Date 2024-10-16
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-20